Abstract
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clinical trials for coronary artery disease.
MeSH terms
-
Animals
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / pharmacokinetics
-
Cardiovascular Agents / therapeutic use*
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / drug therapy*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Factor Xa Inhibitors*
-
Humans
-
Patents as Topic
-
Pyrazoles / adverse effects
-
Pyrazoles / pharmacokinetics
-
Pyrazoles / therapeutic use*
-
Pyridones / adverse effects
-
Pyridones / pharmacokinetics
-
Pyridones / therapeutic use*
-
Structure-Activity Relationship
Substances
-
Cardiovascular Agents
-
Factor Xa Inhibitors
-
Pyrazoles
-
Pyridones
-
apixaban